Wednesday, 1 February, 2023
HomeHealthDCGI gives emergency use approval to Biological E's Corbevax vaccine for kids...

DCGI gives emergency use approval to Biological E’s Corbevax vaccine for kids aged 12-18

It is the second Covid vaccine to get approval for use in children in India after Bharat Biotech's Covaxin.

Text Size:

New Delhi: The Drugs Controller General of India Monday gave emergency use authorisation to Biological E’s Corbevax for use in children between 12 and 18 years of age. It is the second Covid vaccine to get approval for use in children in India.

So far, Bharat Biotech’s Covaxin has been the only vaccine to have been administered to children in India since 3 January.

“Last September, BE received approval to conduct a Phase II/III clinical trial on CORBEVAXTM in children and adolescents aged 5 to 18 years. Based on the no-objection certificate, BE initiated the clinical study in October 2021 and evaluated the available safety and immunogenicity results of the ongoing phase II/III study, which indicated that the vaccine is safe and immunogenic,” Biological E. said in a statement.

Corbevax has been developed by Hyderabad-based biopharmaceutical firm Biological E., US-based Baylor College of Medicine, and American firm Dynavax Technologies.

Corbevax is what is known as a protein subunit vaccine. It contains a protein of the coronavirus, and the body becomes prepared to recognise and launch an immune response against this. This differs from vaccines like Covaxin, which contains the whole virus but in an inactivated form.

The vaccine is administered through the intramuscular route with two doses scheduled 28 days apart and is stored at 2 to 8 degrees Celsius temperature.

Also read: Covid-19 pandemic: Australia reopens border, Hong Kong study says Covid could affect fertility


Subscribe to our channels on YouTube & Telegram

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

Most Popular